PRECEPTORSHIP PROGRAMME

Gastroenteropancreatic Neuroendocrine Neoplasms
Multidisciplinary management, standards of care and future perspectives

PRAGUE
CZECH REPUBLIC

12-13 APRIL 2019

Co-Chairs
Nicola Fazio, IT
Gregory Kaltsas, GR
ESMO PRECEPTORSHIP PROGRAMME
GASTROENTEROPANCREATIC
NEUROENDOCRINE NEOPLASMS
Multidisciplinary management, standards of care
and future perspectives
Prague, Czech Republic
12-13 April 2019

CO-CHAIRS: Nicola Fazio, Italy
              Gregory Kaltsas, Greece

SPEAKERS: Andrea Frilling, United Kingdom
          Rocio Garcia-Carbonero, Spain
          Massimo Milione, Italy
          Vikas Prasad, Germany
          Christos Toumpanakis, United Kingdom
          Marie-Pierre Vulliemo, France

LEARNING OBJECTIVES

- Familiarise with the epidemiology, classification and prognostication of Gastroenteropancreatic (GEP) Neuroendocrine Neoplasms (NEN) patients
- Introduce principles of diagnostic and therapeutic strategy and the role of a multidisciplinary team
- Integrate different therapies in patients with advanced disease
- Familiarise with the genetic aberrations and their evolving role in diagnosis and treatment
- Update of new developments, clinical trials and unmet needs

ACCREDITATION

The programme of this event has been accredited with 9 ESMO-MORA category 1 points.
Recertification is necessary for medical oncologists to remain professionally certified by ESMO. Recertification guarantees
that a certified medical oncologist has continued to update her/his knowledge and continues to possess the necessary skills
and standards for the practice of medical oncology. For further details, please refer to esmo.org.

ACKNOWLEDGEMENTS

This event is supported by an unrestricted educational grant from

IPSEN
Innovation for patient care

ORGANISATION AND CONTACTS

ESMO Head Office
Education Department
Via Ginevra 4
6900 Lugano
Switzerland
Email: courses@esmo.org
www.esmo.org
**Friday, 12 April 2019**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
</table>
| 09:00-09:15 15’ | Welcome and introduction  
Nicola Fazio, IT Gregory Kaltzas, GR |
| 09:15-10:50 95’ | **SESSION 1**  
Current evidence to diagnose and treat GEP-NENs patients  
Chairs: Nicola Fazio, IT Gregory Kaltzas, GR |
| 15’ | Pathologist (terminology and classifications)  
Massimo Milione, IT |
| 15’ | Radiologist  
Marie-Pierre Vuillerm, FR |
| 15’ | Nuclear physician (theranostic role of nuclear medicine)  
Vikas Prasad, DE |
| 10’ | Q&A  
Faculty |
| 10’ | Gastroenterologist (role of endoscopy, chronic diarrhoea)  
Christos Toumpnakis, UK |
| 10’ | Endocrinologist (functioning pancreatic NETs)  
Gregory Kaltzas, GR |
| 10’ | Medical oncologist (metastatic disease)  
Rocio Garcia-Carbonero, ES |
| 10’ | Q&A  
Faculty |
| 10:50-11:15 | Coffee break |
| 11:15-13:00 105’ | **SESSION 2**  
Multispecialist therapeutic approach  
Chairs: Nicola Fazio, IT Gregory Kaltzas, GR |
| 10’ | Participant clinical case discussion  
Faculty |
| 20’ | Tumour board-like discussion  
Nicola Fazio, IT |
| 10’ | Molecular targeted agents in GEP NETs  
Rocio Garcia-Carbonero, ES |
| 10’ | Participant clinical case discussion  
Faculty |
| 20’ | Tumour board-like discussion  
Gregory Kaltzas, GR |
| 10’ | Locally advanced pancreatic NET management  
Andrea Frilling, UK |
| 10’ | Bases for Peptide Receptor Radionuclide Therapy (PRRT) in GEP NETs  
Vikas Prasad, DE |
| 15’ | Q&A  
Faculty |
| 13:00-14:00 | Lunch |
| 14:00-15:30 90’ | **SESSION 3**  
Clinical syndromes  
Chairs: Nicola Fazio, IT Gregory Kaltzas, GR |
| 20’ | Carcinoid syndrome  
Christos Toumpnakis, UK |
| 10’ | Participant clinical case discussion  
Faculty |
| 20’ | Tumour board-like discussion  
Nicola Fazio, IT |
| 20’ | Other clinical syndromes  
Gregory Kaltzas, GR |
| 20’ | Q&A  
Faculty |
<p>| 15:30-16:00 | Coffee break |</p>
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Title</th>
<th>Chairs</th>
</tr>
</thead>
<tbody>
<tr>
<td>16:00-16:40 40’</td>
<td>SESSION 4</td>
<td>Tumour response assessment</td>
<td>Chairs: Nicola Fazio, IT</td>
</tr>
<tr>
<td>10’</td>
<td></td>
<td>How to integrate morphological and functional imaging: Radiologist</td>
<td>Nicola Fazio, IT, GR</td>
</tr>
<tr>
<td>10’</td>
<td></td>
<td>How to integrate morphological and functional imaging: Nuclear Physician</td>
<td>Vikas Prasad, DE</td>
</tr>
<tr>
<td>10’</td>
<td></td>
<td>Radiological tumour response assessment</td>
<td>Marie-Pierre Vuillerme, FR</td>
</tr>
<tr>
<td>10’</td>
<td></td>
<td>Q&amp;A</td>
<td>Faculty</td>
</tr>
<tr>
<td>16:40-17:10 30’</td>
<td>SESSION 5</td>
<td>Miscellaneous</td>
<td>Chairs: Nicola Fazio, IT</td>
</tr>
<tr>
<td>20’</td>
<td></td>
<td>Genetic syndromes: Clinical features</td>
<td>Gregory Kaltsas, GR</td>
</tr>
<tr>
<td>10’</td>
<td></td>
<td>Somatostatin analogs</td>
<td>Nicola Fazio, IT</td>
</tr>
<tr>
<td>19:30</td>
<td></td>
<td>Dinner</td>
<td></td>
</tr>
</tbody>
</table>

**Saturday, 13 April 2019**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Title</th>
<th>Chairs</th>
</tr>
</thead>
<tbody>
<tr>
<td>09:00-10:30 90’</td>
<td>SESSION 6</td>
<td>NEC and MANEC</td>
<td>Chairs: Nicola Fazio, IT</td>
</tr>
<tr>
<td>10’</td>
<td></td>
<td>Mixed (neuroendocrine + non neuroendocrine) GEP neoplasms</td>
<td>Massimo Milione, IT</td>
</tr>
<tr>
<td>20’</td>
<td></td>
<td>High grade GEP NENs medical treatments</td>
<td>Nicola Fazio, IT</td>
</tr>
<tr>
<td>10’</td>
<td></td>
<td>Participant clinical case discussion</td>
<td>Faculty</td>
</tr>
<tr>
<td>20’</td>
<td></td>
<td>Tumour board-like discussion</td>
<td>Nicola Fazio, IT</td>
</tr>
<tr>
<td>10’</td>
<td></td>
<td>Participant clinical case discussion</td>
<td>Faculty</td>
</tr>
<tr>
<td>20’</td>
<td></td>
<td>Tumour board-like discussion</td>
<td>Gregory Kaltsas, GR</td>
</tr>
<tr>
<td>10:30-11:00</td>
<td></td>
<td>Coffee break</td>
<td></td>
</tr>
<tr>
<td>11:00-12:45 105’</td>
<td>SESSION 7</td>
<td>Toxicity management</td>
<td>Chairs: Nicola Fazio, IT</td>
</tr>
<tr>
<td>10’</td>
<td></td>
<td>PRRT toxicity and safety</td>
<td>Vikas Prasad, DE</td>
</tr>
<tr>
<td>10’</td>
<td></td>
<td>Endocrinological toxicity</td>
<td>Gregory Kaltsas, GR</td>
</tr>
<tr>
<td>10’</td>
<td></td>
<td>Participant clinical case discussion</td>
<td>Faculty</td>
</tr>
<tr>
<td>20’</td>
<td></td>
<td>Tumour board-like discussion</td>
<td>Nicola Fazio, IT</td>
</tr>
<tr>
<td>10’</td>
<td></td>
<td>Chemotherapy and molecular targeted agents toxicity / safety</td>
<td>Rocio Garcia-Carbonero, ES</td>
</tr>
<tr>
<td>30’</td>
<td></td>
<td>Summarising general approach to GEP NENs patients</td>
<td>Gregory Kaltsas, GR, Nicola Fazio, IT</td>
</tr>
<tr>
<td>15’</td>
<td></td>
<td>Q&amp;A</td>
<td>Faculty</td>
</tr>
<tr>
<td>12:45-13:00 15’</td>
<td></td>
<td>Conclusion and farewell</td>
<td>Chairs: Nicola Fazio, IT</td>
</tr>
<tr>
<td>13:00-14:00</td>
<td></td>
<td>Lunch</td>
<td></td>
</tr>
</tbody>
</table>